Patients treated with an experimental Amicus Therapeutics drug for Pompe disease continued to show improvement in their ability to walk, move, and breathe after as long as one year on the therapy, according to the latest clinical trial results from the rare disease drug developer.
The open-label study is small, testing the drug in just 20 patients. But the latest results build on interim data that the company released last October assessing patients at the six- and nine-month marks. Cranbury, NJ-based Amicus (NASDAQ: FOLD) is scheduled to present the latest results Thursday in San Diego at the WORLDSymposium, an annual… Read more »
UNDERWRITERS AND PARTNERS